Retatrutide Cycle

Retatrutide is the most potent incretin mimetic currently available, activating three receptors simultaneously: GLP-1, GIP, and glucagon. Early clinical data shows weight reductions of up to 24% – surpassing both semaglutide and tirzepatide. The glucagon receptor activation adds increased energy expenditure and hepatic fat mobilisation that single and dual agonists cannot achieve.

As a newer compound with less long-term data, retatrutide is primarily used by experienced researchers. The multi-vial cycle ensures uninterrupted supply for proper titration at a significant cost savings.